CA2885519A1 - Recombinant clostridium botulinum neurotoxins - Google Patents

Recombinant clostridium botulinum neurotoxins Download PDF

Info

Publication number
CA2885519A1
CA2885519A1 CA2885519A CA2885519A CA2885519A1 CA 2885519 A1 CA2885519 A1 CA 2885519A1 CA 2885519 A CA2885519 A CA 2885519A CA 2885519 A CA2885519 A CA 2885519A CA 2885519 A1 CA2885519 A1 CA 2885519A1
Authority
CA
Canada
Prior art keywords
protein
bont
sequence
chain
trypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2885519A
Other languages
English (en)
French (fr)
Inventor
Aimee Cossins
Matthew Beard
Philip Marks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Ipsen Bioinnovation Ltd
Original Assignee
Syntaxin Ltd
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd, Ipsen Biopharm Ltd filed Critical Syntaxin Ltd
Publication of CA2885519A1 publication Critical patent/CA2885519A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2885519A 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins Abandoned CA2885519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
GB1219602.8 2012-10-31
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
CA2885519A1 true CA2885519A1 (en) 2014-05-08

Family

ID=47358958

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2885519A Abandoned CA2885519A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Country Status (26)

Country Link
US (1) US10030238B2 (enExample)
EP (3) EP2914282B1 (enExample)
JP (2) JP2019068823A (enExample)
KR (2) KR102188539B1 (enExample)
CN (2) CN104755098A (enExample)
AR (2) AR093309A1 (enExample)
AU (3) AU2013340610B2 (enExample)
BR (1) BR112015005384A2 (enExample)
CA (1) CA2885519A1 (enExample)
DK (2) DK3326644T3 (enExample)
EA (1) EA201590794A8 (enExample)
ES (2) ES2662402T3 (enExample)
GB (1) GB201219602D0 (enExample)
HU (2) HUE048802T2 (enExample)
IL (1) IL237623B (enExample)
IN (1) IN2015MN00436A (enExample)
MX (2) MX367080B (enExample)
NO (1) NO2914282T3 (enExample)
NZ (1) NZ705575A (enExample)
PL (2) PL2914282T3 (enExample)
PT (2) PT3326644T (enExample)
SG (2) SG10201701140WA (enExample)
TW (3) TW202012622A (enExample)
UA (1) UA118837C2 (enExample)
WO (1) WO2014068317A1 (enExample)
ZA (1) ZA201501449B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
CN107548402B (zh) * 2015-03-26 2022-08-19 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
SG11201805195YA (en) 2016-03-02 2018-07-30 Merz Pharma Gmbh & Co Kgaa Composition comprising botulinum toxin
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
CN110072880B (zh) 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
TWI773686B (zh) 2016-09-13 2022-08-11 美商愛力根公司 非蛋白梭菌毒素組成物
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
EP3694489A4 (en) 2017-10-11 2021-06-30 Illustris Pharmaceuticals, Inc. METHOD AND COMPOSITION OF TOPICAL ADMINISTRATION
CA3220194A1 (en) * 2018-01-29 2019-08-01 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
CA2336587A1 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
EP1206554B2 (en) 1999-08-25 2010-10-20 Allergan, Inc. Activatable recombinant neurotoxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
US20110111483A1 (en) * 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
AU2005327458B2 (en) * 2005-03-03 2011-12-15 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
DE602006013481D1 (de) * 2005-09-19 2010-05-20 Allergan Inc Mit clostriedientoxin aktivierbare clostridientoxine
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
AU2007272517B2 (en) * 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US8486422B2 (en) * 2007-07-26 2013-07-16 Allergan, Inc. Methods of activating clostridial toxins
RU2535003C2 (ru) * 2008-12-10 2014-12-10 Аллерган, Инк. Фармацевтические композиции токсина клостридий
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
CA2758274C (en) * 2009-04-14 2018-04-10 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
JP2013514091A (ja) * 2009-12-16 2013-04-25 アラーガン、インコーポレイテッド 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
CN110072880B (zh) * 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素

Also Published As

Publication number Publication date
TW201825680A (zh) 2018-07-16
IL237623B (en) 2019-05-30
KR102264478B1 (ko) 2021-06-15
HK1208359A1 (en) 2016-03-04
EP3673914A1 (en) 2020-07-01
PT3326644T (pt) 2020-05-29
MX2015005156A (es) 2015-09-23
AR093309A1 (es) 2015-05-27
CN104755098A (zh) 2015-07-01
AU2018203556A1 (en) 2018-06-07
ES2662402T3 (es) 2018-04-06
HUE036764T2 (hu) 2018-07-30
GB201219602D0 (en) 2012-12-12
PL3326644T3 (pl) 2020-08-24
TWI673361B (zh) 2019-10-01
AU2020244481A1 (en) 2020-10-29
PL2914282T3 (pl) 2018-07-31
DK3326644T3 (da) 2020-05-11
WO2014068317A1 (en) 2014-05-08
ES2788199T3 (es) 2020-10-20
SG11201502372SA (en) 2015-05-28
CN110499321A (zh) 2019-11-26
PT2914282T (pt) 2018-03-13
TW202012622A (zh) 2020-04-01
EA201590794A8 (ru) 2016-01-29
AU2013340610A1 (en) 2015-03-19
IL237623A0 (en) 2015-04-30
EP3326644B1 (en) 2020-03-04
AU2018203556B2 (en) 2020-08-20
IN2015MN00436A (enExample) 2015-09-04
KR20200110470A (ko) 2020-09-23
AR117738A2 (es) 2021-08-25
KR20150094590A (ko) 2015-08-19
TW201435084A (zh) 2014-09-16
TWI626307B (zh) 2018-06-11
BR112015005384A2 (pt) 2017-08-08
SG10201701140WA (en) 2017-04-27
US20150247139A1 (en) 2015-09-03
AU2013340610B2 (en) 2018-02-22
EP3326644A1 (en) 2018-05-30
MX367080B (es) 2019-08-05
JP2019068823A (ja) 2019-05-09
JP2020078321A (ja) 2020-05-28
EP3673914B1 (en) 2021-10-27
HUE048802T2 (hu) 2020-08-28
ZA201501449B (en) 2016-08-31
EA201590794A1 (ru) 2015-08-31
EP2914282B1 (en) 2017-12-20
EP2914282A1 (en) 2015-09-09
KR102188539B1 (ko) 2020-12-09
UA118837C2 (uk) 2019-03-25
NZ705575A (en) 2019-08-30
NO2914282T3 (enExample) 2018-05-19
DK2914282T3 (en) 2018-02-26
MX2019009222A (es) 2019-11-21
US10030238B2 (en) 2018-07-24

Similar Documents

Publication Publication Date Title
AU2018203556B2 (en) Recombinant clostridium botulinum neurotoxins
US20230285521A1 (en) Composition comprising recombinant clostridium neurotoxin
JP2015534814A (ja) 組換えクロストリジウムボツリヌス神経毒
HK1254485B (en) Recombinant clostridium botulinum neurotoxins
HK1254485A1 (en) Recombinant clostridium botulinum neurotoxins
HK40015514A (en) Recombinant clostridium botulinum neurotoxins
HK1208359B (en) Recombinant clostridium botulinum neurotoxins
EA040938B1 (ru) Получение рекомбинантных нейротоксинов clostridium botulinum

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181004

FZDE Discontinued

Effective date: 20211229